Rapid Microbiology Methods Industry Concerns Jeanne Moldenhauer Vectech Pharmaceutical Consultants, Inc.

Slides:



Advertisements
Similar presentations
Mathematics Glossary. This glossary is for people to use if they dont know a strategy to use when they are stuck. Questioning and Problem Posing.
Advertisements

ICH Q4B Regulatory Acceptance of Analytical Procedures and/or Acceptance Criteria (RAAPAC) Overview and Update Robert H. King, Sr. Office of Pharmaceutical.
Laboratory Automation & Instrumentation Power Protection Systems Case Study Baxter Healthcare.
Regulatory Challenges in the Cell Preparation Facility Adrian Gee Center for Cell & Gene Therapy Regulatory Challenges in the Cell Preparation Facility.
Florida Pilot Initiative for the Performance Approach to Measurement Systems Stephen Arms Florida Department of Health.
VALIDATION What is the new guidance?. What is a Compliance Policy Guide? Explain FDA policy on regulatory issues CGMP regulations and application commitments.
CBER 510(k) Challenges and Strategies Susan Finneran Director of Clinical and Regulatory Affairs.
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development IND Regulatory.
Validation of Microbiological Methods for Use in the Food Industry Brazilian Association for Food Protection 6 th International Symposium Sao Paulo, Brazil.
Integrating CMC Review & Inspection Industry Recommendations Joe Anisko April 24, 2003.
Rapid Microbiology Methods A Regulatory Viewpoint Bryan S. Riley, Ph.D. U.S. Food and Drug Administration Center for Drug Evaluation and Research Office.
Pharmaceutical Nomenclature Issues and challenges Moheb M. Nasr, Ph.D. Acting Director Office of New Drug Chemistry (ONDC) OPS, CDER, FDA Advisory Committee.
Transition to Inspections: USP, 21 CFR 212, And Beyond? Panel Discussion Ravi S. Harapanhalli, Ph.D Louis Marzella, MD Ravindra Kasliwal, Ph.D Wendy Sanhai,
(c) 2002 Jeanne Moldenhauer1 Validation of Rapid Microbiology Systems Based upon PDA Technical Report No. 33.
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development Critical Path.
Special Topics in IND Regulation
FIELD COMPLIANCE UPDATE CDR Thomas R. Berry, RPh FDA, Investigator RAL-RP / ATL-DO.
The Role of Biotechnology in a Sustainable Food Supply Section 3 : Risk Assessment Peggy G. Lemaux, University of California, Berkeley, California, U.S.A.
WHO Prequalification Program Workshop, Kiev, Ukraine, June 25-27,2007.
1 Revisions to 21 CFR Supplements and Other Changes to an Approved Application PhRMA Perspective FDA Public Meeting – 7 Feb 2007.
Background Donor Suitability Consultation was held in Atlanta June 26-27, 2001 To review and consult on the 1994 CDC Guidelines for Preventing Transmission.
BIOTECHNOLOGIES AS A CONTEXT FOR ENHANCING STUDENTS ABILITY TO ASK MEANINGFUL QUESTIONS ABOUT ABSTRACT BIOLOGICAL PROCESSES Dr. GILA OLSHER
MethodGXP The Solution for the Confusion.
DOCUMENTATION.
© 2010 Premier, Inc. 9/8/ NAVIGATING THE DRUG SHORTAGE CRISIS IN AMERICAN HEALTHCARE Coleen A. Cherici, RPh, MBA Director of Pharmacy Consulting.
Feldman 20 February Pilot Plant through Scale-Up Manufacturing Martha A. Feldman, RAC Drug & Device Development Co., Inc. P.O. Box 3515 Redmond,
Food Safety Regulation and Standards
Reporting Unanticipated Problems and Adverse Events: A Change in Policy Mary A. Banks RN, BS, BSN Director, BUMC IRB Wednesday, November 14, 2007.
Changes without Prior Approval Breakout Session Summary Rick Smith Aventis Pasteur, Inc.
© Pharmaceutical Consultancy Services, All rights reserved. Quality System(s)
School Audits Presented by: Office of the State Auditor Performance Audit Division.
Blend Uniformity - PQRI Research
CBER HCT/P Contamination Prevention and Biologic Product Sterility Regulations Applicable to PBSCs Cell Therapy Liaison Meeting June 16, 2006 Ellen F.
Apheresis Blood Components
1 PAT and Biological Products Tom Layloff FDA-SGE Management Sciences for Health The views expressed here are those of the author and not necessarily.
Pre kick off meeting 1 1 NCHRP_22_24 January CME Activities 1.Define reporting procedures for simulations (data output, variables, etc) 2.Define.
Leukocyte-Reduced Blood Components Lore Fields MT(ASCP)SBB Consumer Safety Officer, DBA, OBRR, CBER September 16, 2009.
1 Regulatory Aspects of Pharmaceutical Excipients PQRI Workshop Nick Buhay Acting Director Division of Manufacturing and Product Quality Office of Compliance.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
THE CONCEPTS of PERFORMANCE STANDARDS, CUMULATIVE STEPS AND VALIDATION STUDIES Dr. John Kvenberg, Acting Director, Office of Field Programs July 15, 1999.
Overview of FDA's Regulatory Framework for PET Drugs
The FDA Regulatory and Compliance Symposium Preparing for the FDA’s Risk-Based Inspections Presented By: Martin Browning, EduQuest, Inc.
Risk-Based CMC Review - OGD Perspective Gary J. Buehler, R.Ph. Director Office of Generic Drugs July 21, 2004 Advisory Committee for Pharmaceutical Science.
Molecule-to-Market-Place Quality
Expectations for Facilities & cGMPs Biological Response Modifiers Advisory Committee Meeting October 9, 2003 Nicholas Obiri, Ph.D. CBER.
FDA Regulatory and Compliance Symposium
Progress in FDA’s Drug Product Quality Initiative Janet Woodcock, M.D. November 13, 2003.
©2007 Fredrikson & Byron P.A. Presented by
Jaro Vostal, MD, PhD Division of Hematology, OBRR, CBER, FDA
Second Meeting of the FDA/ACPS Process Analytical Technology: Closing Remarks Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical Sciences.
Drug Quality Regulations for the 21 st Century PhRMA Perspective Manufacturing Subcommittee Meeting – May 21, 2003 Gerry Migliaccio Pfizer Inc.
Use of Risk-based Approach for Regulating CMC Changes to Approved Applications FDA Public Meeting February 7, 2007.
COPYRIGHT ALL RIGHTS RESERVED. LEGAL DISCLOSURE. November 25, 2002 PRESENTATION TO: Public Hearing: FDA Regulation of Combination Products November.
Scientific Explanation  Suppose we assume that explanation and prediction of phenomena are the goals/purposes of science  Suppose we also assume that.
Artefact Projects Mr Harbron Year 12 Enhancement Coordinator and EPQ Centre Coordinator.
Product & Process Working Group February 26, 2002.
Tampon Global Regulatory overview Erly Evita Product Safety & Regulatory Affairs Procter & Gamble Far East Inc. Kobe Technical Center, Japan.
Bidding Strategies. Outline of Presentation Markup Expected Profit Cost of Construction Maximizing Expected Profit Case 1: Single Known Competitor Case.
Compliance Update Allergenic Products Advisory Committee Meeting March 15, 2002 Teddi Lopez DCM/OCBQ Center for Biologics Evaluation and Research.
Scientific Notation Objectives: SWBAT convert between standard notation and scientific notation by hand and by calculators.
Patient Engagement in Drug Development: Experiences, Good Practices and Lessons Learned Lana Skirboll VP Science Policy Sanofi October 28, 2016, National.
November 9, 2015 February 20, 2017 Using real world evidence – industry perspective Pma indication expansion Melissa hasenbank, phd Sr. Clinical Research.
Bidding Strategies.
Premarket Notification 510(k) process
Nega Beru, Ph. D. Director, Office of Food Safety
Bio-Facility Qualification, Start-Up & Licensure
Median submission gap, median approval time and percentage approved as expedited for new active substances (NASs) approved by six authorities:
Analytical Method Validation PAI Readiness / Certification
7 Chapter Rational Numbers as Decimals and Percent
7 Chapter Decimals: Rational Numbers and Percent
Presentation transcript:

Rapid Microbiology Methods Industry Concerns Jeanne Moldenhauer Vectech Pharmaceutical Consultants, Inc.

Business Objectives  Laboratory Compliance to FDA requirements  Low cost provider of high quality products  Reduce overhead  Just-in-time production  Reduce inventory hold times  Expedite product approvals  State of the art technology usage

Concerns Over Use of Rapid Methods  Regulatory review and approval expectations are not clear  Cost of equipment is high and perceived regulatory risk is high  Most types of equipment for rapid methods cannot be validated to be equivalent, due to superior technology  Compliance issues vs. Submission issues  Scientific Issues

Case Study 1: Water Testing  Reviewing division indicated “unofficially” it was a compliance issue  Local District consulted and issues were discussed, e.g., equivalence and number of tests  Advised that: –When approved technology would raise the bar. –Compliance is not likely to move on this issue very very slowly. –ROI was dependent upon using testing method during validation and validation could not be held for an indefinite time period.

Case Study 2: Biological Indicator Enumeration  Regulatory Strategy: Develop method, validate and submit with a drug where a known deficiency would occur. Have parallel testing, in case new method was not approved.  USP Stimuli to Revision indicated method was suitable for bacteria, fungi and spores.  Started to develop method

Case Study 2: Biological Indicators cont.  Counts were erratic and went to the vendor  Modified test several times, with some counts being lower than traditional method.  Modified test and control counts were good but stressed organism test counts were up to 4 logs higher  What does that say about the sterilization model?

Case Study 2: Biological Indicators cont.  Studies done and showed that indicator organism was dying in expected log fashion, with good approximation of D- value  Supposed that counts still were not true  Eventually, was able to find out scientifically that clumping was an issue  Final method yielded counts approximately one-half log higher for stressed organisms